Medpace Holdings Inc (NASDAQ:MEDP) – Equities researchers at William Blair raised their FY2017 earnings estimates for shares of Medpace Holdings in a research report issued on Wednesday. William Blair analyst J. Kreger now expects that the company will post earnings per share of $1.50 for the year, up from their previous estimate of $1.43. William Blair currently has a “Market Perform” rating on the stock. William Blair also issued estimates for Medpace Holdings’ Q4 2017 earnings at $0.38 EPS, Q3 2018 earnings at $0.43 EPS, FY2018 earnings at $1.68 EPS, Q2 2019 earnings at $0.46 EPS, Q3 2019 earnings at $0.50 EPS, FY2019 earnings at $1.94 EPS and FY2020 earnings at $2.23 EPS.

MEDP has been the subject of several other reports. Raymond James Financial, Inc. assumed coverage on shares of Medpace Holdings in a research report on Friday, September 29th. They set a “market perform” rating for the company. KeyCorp reissued a “hold” rating on shares of Medpace Holdings in a research report on Tuesday, October 17th. Robert W. Baird reissued a “hold” rating and set a $32.00 price target on shares of Medpace Holdings in a research report on Monday, October 9th. Zacks Investment Research raised shares of Medpace Holdings from a “hold” rating to a “strong-buy” rating and set a $38.00 price target for the company in a research report on Saturday, September 9th. Finally, Jefferies Group LLC increased their price target on shares of Medpace Holdings from $34.00 to $38.00 and gave the company a “hold” rating in a research report on Wednesday. Eight investment analysts have rated the stock with a hold rating and one has given a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average target price of $36.20.

ILLEGAL ACTIVITY WARNING: “FY2017 EPS Estimates for Medpace Holdings Inc (MEDP) Lifted by William Blair” was originally published by American Banking News and is the property of of American Banking News. If you are accessing this report on another domain, it was illegally stolen and republished in violation of international copyright legislation. The correct version of this report can be read at https://www.americanbankingnews.com/2017/11/02/fy2017-eps-estimates-for-medpace-holdings-inc-medp-lifted-by-william-blair.html. Medpace Holdings (NASDAQ:MEDP) last released its quarterly earnings data on Monday, October 30th. The company reported $0.40 earnings per share for the quarter, beating analysts’ consensus estimates of $0.36 by $0.04. The business had revenue of $98.68 million during the quarter, compared to analyst estimates of $96.84 million. Medpace Holdings had a net margin of 8.89% and a return on equity of 6.80%. Medpace Holdings’s revenue was up 4.1% compared to the same quarter last year. During the same period last year, the business earned $0.40 EPS.

Institutional investors and hedge funds have recently bought and sold shares of the company. First Quadrant L P CA acquired a new position in shares of Medpace Holdings during the third quarter valued at about $119,000. American International Group Inc. acquired a new position in shares of Medpace Holdings during the first quarter valued at about $145,000. Tudor Investment Corp ET AL increased its holdings in shares of Medpace Holdings by 16.4% during the first quarter. Tudor Investment Corp ET AL now owns 6,864 shares of the company’s stock valued at $205,000 after acquiring an additional 967 shares in the last quarter. Susquehanna International Group LLP acquired a new position in shares of Medpace Holdings during the second quarter valued at about $220,000. Finally, Credit Suisse AG acquired a new position in shares of Medpace Holdings during the first quarter valued at about $231,000. Hedge funds and other institutional investors own 16.32% of the company’s stock.

In other Medpace Holdings news, major shareholder Medpace Limited Partnership sold 2,000,000 shares of the stock in a transaction dated Tuesday, August 22nd. The shares were sold at an average price of $30.27, for a total transaction of $60,540,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 25.80% of the company’s stock.

About Medpace Holdings

Medpace Holdings, Inc is a clinical contract research organization. The Company provides clinical research-based drug and medical device development services. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focus on full service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support.

Earnings History and Estimates for Medpace Holdings (NASDAQ:MEDP)

Receive News & Ratings for Medpace Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace Holdings Inc and related companies with MarketBeat.com's FREE daily email newsletter.